Raloxifene [orch, phsu]
serum triglycerides [lbpr]
Women [popg]
History [ocdi]
Hypertriglyceridaemia [fndg]
Oral [spco]
estrogen therapy [topp]
Objective [inpr]
Raloxifene Hydrochloride [orch, phsu]
Selective Estrogen Receptor Modulator [horm, phsu]
Date [tmco]
Hypertriglyceridaemia [fndg]
Normal [qlco]
diabetic [fndg]
Women [popg]
Study [mnob]
Design [acty]
Raloxifene [orch, phsu]
serum triglycerides [lbpr]
postmenopausal [tmco]
Women [popg]
History [ocdi]
Increased [qnco]
Hypertriglyceridaemia [fndg]
Oral [spco]
Estrogen [horm, phsu, strd]
Research Design [resa]
Methods [inpr]
thi [euka]
Single [popg]
Center [spco]
Uncontrolled [qlco]
Open Label Study [resa]
investigating [ftcn]
effects [qlco]
weeks [tmco]
Raloxifene [orch, phsu]
mg day [qnco]
therapy [ftcn]
Plasma lipids [lbpr]
Study Subject [grup]
postmenopausal [tmco]
Women [popg]
Age [orga]
Documented [hlca]
History [ocdi]
Oral [spco]
Estrogen [horm, phsu, strd]
Induced [ftcn]
Hypertriglyceridaemia [fndg]
serum triglycerides [lbpr]
mmol/L [qnco]
mg dl [qnco]
Study [mnob]
Subject [grup]
Withdraw [acty]
Trial [resa]
Marked [qlco]
Hypertriglyceridaemia [fndg]
mmol/L [qnco]
mg dl [qnco]
Raloxifene [orch, phsu]
therapy [ftcn]
Women [popg]
baseline [bodm]
Triglyceride [bacs, lipd]
glucose levels [lbtr]
treated [topp]
Lipid lowering agents [phsu]
Likely [qlco]
Diabetes [dsyn]
Study Subject [grup]
Remaining [qlco]
Nine [qnco]
Patients [podg]
COMPLETED [qlco]
Trial [resa]
experience [menp]
Triglyceride level [lbtr]
baseline [bodm]
End Point [qlco]
Raloxifene [orch, phsu]
treatment [ftcn]
Decrease [qlco]
hepatic lipase activity [moft]
HDL2 [gngm]
Levels [qlco]
P NOS [aapp, imft]
Conclusions [idcn]
Patients [podg]
Previous [tmco]
History [ocdi]
Hypertriglyceridaemia [fndg]
Oral [spco]
estrogen therapy [topp]
Serum triglyceride levels [lbpr]
monitor [hlca]
Beginning [tmco]
Raloxifene [orch, phsu]
therapy [ftcn]
therapy [ftcn]
Beginning [tmco]
Raloxifene [orch, phsu]
